PMC:7532482 / 15563-16179 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T58","span":{"begin":378,"end":392},"obj":"Disease"},{"id":"T59","span":{"begin":385,"end":392},"obj":"Disease"},{"id":"T60","span":{"begin":404,"end":425},"obj":"Disease"},{"id":"T61","span":{"begin":416,"end":425},"obj":"Disease"},{"id":"T62","span":{"begin":487,"end":512},"obj":"Disease"},{"id":"T63","span":{"begin":503,"end":512},"obj":"Disease"},{"id":"T64","span":{"begin":542,"end":553},"obj":"Disease"},{"id":"T65","span":{"begin":542,"end":551},"obj":"Disease"}],"attributes":[{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005055"},{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0005089"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0005794"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A62","pred":"mondo_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/MONDO_0005132"},{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A64","pred":"mondo_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/MONDO_0005344"},{"id":"A65","pred":"mondo_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T158","span":{"begin":287,"end":292},"obj":"http://purl.obolibrary.org/obo/OGG_0000000002"},{"id":"T159","span":{"begin":436,"end":445},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T160","span":{"begin":481,"end":486},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T161","span":{"begin":520,"end":529},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T162","span":{"begin":552,"end":553},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T102","span":{"begin":427,"end":430},"obj":"Chemical"},{"id":"T103","span":{"begin":514,"end":516},"obj":"Chemical"}],"attributes":[{"id":"A102","pred":"chebi_id","subj":"T102","obj":"http://purl.obolibrary.org/obo/CHEBI_84123"},{"id":"A103","pred":"chebi_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A104","pred":"chebi_id","subj":"T103","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}

{"project":"LitCovid-PubTator","denotations":[{"id":"207","span":{"begin":427,"end":430},"obj":"Gene"},{"id":"208","span":{"begin":431,"end":435},"obj":"Gene"},{"id":"209","span":{"begin":514,"end":519},"obj":"Gene"},{"id":"210","span":{"begin":378,"end":425},"obj":"Disease"},{"id":"211","span":{"begin":457,"end":479},"obj":"Disease"},{"id":"212","span":{"begin":487,"end":512},"obj":"Disease"},{"id":"213","span":{"begin":542,"end":553},"obj":"Disease"}],"attributes":[{"id":"A207","pred":"tao:has_database_id","subj":"207","obj":"Gene:5973"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"Gene:177"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"Gene:3605"},{"id":"A210","pred":"tao:has_database_id","subj":"210","obj":"MESH:D012514"},{"id":"A211","pred":"tao:has_database_id","subj":"211","obj":"MESH:D048909"},{"id":"A212","pred":"tao:has_database_id","subj":"212","obj":"MESH:D003586"},{"id":"A213","pred":"tao:has_database_id","subj":"213","obj":"MESH:D006509"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T19","span":{"begin":378,"end":392},"obj":"Phenotype"},{"id":"T20","span":{"begin":542,"end":551},"obj":"Phenotype"}],"attributes":[{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0100726"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T11","span":{"begin":436,"end":453},"obj":"http://purl.obolibrary.org/obo/GO_0007165"},{"id":"T12","span":{"begin":436,"end":445},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T13","span":{"begin":520,"end":537},"obj":"http://purl.obolibrary.org/obo/GO_0007165"},{"id":"T14","span":{"begin":520,"end":529},"obj":"http://purl.obolibrary.org/obo/GO_0023052"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}

{"project":"LitCovid-sentences","denotations":[{"id":"T131","span":{"begin":0,"end":118},"obj":"Sentence"},{"id":"T132","span":{"begin":119,"end":174},"obj":"Sentence"},{"id":"T133","span":{"begin":175,"end":293},"obj":"Sentence"},{"id":"T134","span":{"begin":294,"end":616},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The pathways that were significantly affected by SFJDC in the process of treating NCP were identified by KEGG pathway. 110 KEGG pathways were significantly enriched (P\u003c0.05). Top twenty pathways were shown in Figure 7, color represented P value and size of the spot represented count of genes. Based on the analysis of KEGG pathway data (Table 6), the top five pathways such as Kaposi sarcoma-associated herpesvirus infection, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, IL-17 signaling pathway and Hepatitis B, might be the core pharmacological mechanism of SFJDC for NCP."}